Search hospitals > Texas > Houston
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Claim this profileHouston, Texas 77030
Global Leader in Cancer
Global Leader in Uterine Tumors
Conducts research for Relapse
Conducts research for Skin Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
295 reported clinical trials
48 medical researchers
Summary
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Uterine Tumors, Relapse, Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 495 conditions. There are 48 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jennifer Foster, MDBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center2 years of reported clinical research
Expert in Neuroblastoma
Expert in Cancer
34 reported clinical trials
53 drugs studied
Patricia Baxter, MDTexas Children's Hospital2 years of reported clinical research
Expert in Brain Tumor
Expert in Cerebral Gliomas
32 reported clinical trials
40 drugs studied
Mothaffar Rimawi, MDBaylor College of Medicine5 years of reported clinical research
Studies Breast Cancer
Studies Skin Cancer
11 reported clinical trials
23 drugs studied
Ahmed ElkhananyUniversity of Alabama at Birmingham Cancer Center1 year of reported clinical research
Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Breast Cancer
Cancer
Lung Cancer
Skin Cancer
Breast cancer
Bladder Cancer
Acute Lymphoblastic Leukemia
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Relapse
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center?
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Uterine Tumors, Relapse, Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 495 conditions. There are 48 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.